79 filings
Page 4 of 4
8-K
gq3e6nqryieuecjte
15 Oct 19
PhaseBio Announces First Patient Dosed in Phase 2b Clinical Trial of PB2452 for Reversal of the Antiplatelet Activity of Ticagrelor
8:03am
8-K
u3vuj48xi10i8u0
24 Sep 19
PhaseBio Announces Completion of Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor
4:05pm
8-K
7ucd4bweibew lrbt
14 Aug 19
Regulation FD Disclosure
12:00am
8-K
d7j981vose3m
13 Aug 19
PhaseBio Reports Second Quarter 2019 Financial Results and Recent Corporate Progress
4:05pm
8-K
udkc59s8
1 Jul 19
Other Events
8:02am
8-K
dog7z7tvm nbh
17 Jun 19
Other Events
4:05pm
8-K
7ix1w ap5ah
13 May 19
Submission of Matters to a Vote of Security Holders
12:00am
8-K
c3h qih7b
9 May 19
PhaseBio Reports First Quarter 2019 Financial and Business Results
4:05pm
8-K
x0dpwf9nlbxm5uu
10 Apr 19
Regulation FD Disclosure
8:00am
8-K
bihkz6228w 8aviu
9 Apr 19
PhaseBio Announces Global License of PB1023 for the Treatment of Sarcopenia-Related Diseases to ImmunoForge
8:01am
8-K
woo291d
8 Apr 19
PhaseBio Receives FDA Breakthrough Therapy Designation for PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor
4:25pm
8-K
4ndl7vfdsl7mk
4 Apr 19
Entry into a Material Definitive Agreement
4:05pm
8-K
9kdnrmd ygras
26 Mar 19
PhaseBio Reports Fourth Quarter and Full-Year 2018 Financial and Business Results
4:05pm
8-K
66zf2sji1y2xh31dbv
21 Mar 19
PB2452 achieved immediate and sustained reversal of ticagrelor antiplatelet effects
4:05pm
8-K
mxpp712w4zoirr5
4 Mar 19
PhaseBio Appoints Richard A. van den Broek to Board of Directors
8:00am
8-K
l2c0a44tsb8
25 Jan 19
Material Modifications to Rights of Security Holders
4:05pm
8-K
uksz2ej9w3aay
17 Dec 18
PhaseBio Appoints Edmund P. Harrigan to Board of Directors
4:36pm
8-K
gr1e9pszibswr7
29 Nov 18
PhaseBio Reports Third Quarter 2018 Financial and Business Results
4:41pm
8-K
v5r1pc
22 Oct 18
Amendments to Articles of Incorporation or Bylaws
4:34pm